Global X HealthTech ETF (NASDAQ:HEAL) Stock Short Interest Report for October

Global X HealthTech ETF (NASDAQ:HEAL) saw a large growth in short interest in the month of October. As of October 30th, there was short interest totaling 33,454 shares, a growth of 1,608.6% from the October 15th total of 1,958 shares. Based on an average trading volume of 18,461 shares, the short-interest ratio is currently 1.8 days. Approximately 2.7% of the shares of the company are sold short.

Global X HealthTech ETF Trading Down 2.1%

Shares of NASDAQ:HEAL traded down $0.66 during midday trading on Tuesday, hitting $30.70. The stock had a trading volume of 5,564 shares, compared to its average volume of 10,857. The company has a market capitalization of $38.06 million, a PE ratio of 28.10 and a beta of 1.12. The stock has a 50 day moving average price of $29.84 and a two-hundred day moving average price of $27.32. Global X HealthTech ETF has a 1 year low of $23.00 and a 1 year high of $32.15.

Institutional Investors Weigh In On Global X HealthTech ETF

Hedge funds have recently added to or reduced their stakes in the company. Royal Bank of Canada increased its position in Global X HealthTech ETF by 39.4% during the 1st quarter. Royal Bank of Canada now owns 2,603 shares of the company’s stock worth $62,000 after purchasing an additional 736 shares during the period. Farther Finance Advisors LLC raised its stake in shares of Global X HealthTech ETF by 4.3% during the 3rd quarter. Farther Finance Advisors LLC now owns 23,037 shares of the company’s stock worth $680,000 after buying an additional 950 shares in the last quarter. Finally, C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors lifted its holdings in shares of Global X HealthTech ETF by 28.3% in the 3rd quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors now owns 195,122 shares of the company’s stock valued at $5,758,000 after buying an additional 43,075 shares during the period.

Global X HealthTech ETF Company Profile

An ETF that invests in companies at the intersection of healthcare and technology, targeting innovations in drug discovery, medical devices, consumer healthcare, and analytics.